<p>随着亚洲市场在表现不一和经济变动的背景下进行调整，投资者密切关注在美中贸易紧张局势缓解和日本股市创纪录高点的情况下寻找机会。在这种情况下，识别具有强大基本面的被低估股票可以提供资本增值的潜力，尤其是在区域经济适应不断变化的全球条件时。</p>
<h3>基于现金流的亚洲十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估计）</strong></td>
<td><strong>折扣（估计）</strong></td>
</tr>
<tr>
<td>西安国际医疗投资（SZSE:000516）</td>
<td>CN¥4.76</td>
<td>CN¥9.38</td>
<td>49.3%</td>
</tr>
<tr>
<td>Visional（TSE:4194）</td>
<td>¥9984.00</td>
<td>¥19579.10</td>
<td>49%</td>
</tr>
<tr>
<td>新西兰国王三文鱼投资（NZSE:NZK）</td>
<td>NZ$0.195</td>
<td>NZ$0.39</td>
<td>49.5%</td>
</tr>
<tr>
<td>美图（SEHK:1357）</td>
<td>HK$8.80</td>
<td>HK$17.19</td>
<td>48.8%</td>
</tr>
<tr>
<td>联创电子科技有限公司（SZSE:002036）</td>
<td>CN¥10.08</td>
<td>CN¥19.99</td>
<td>49.6%</td>
</tr>
<tr>
<td>Insource（TSE:6200）</td>
<td>¥845.00</td>
<td>¥1665.99</td>
<td>49.3%</td>
</tr>
<tr>
<td>Ibiden 有限公司（TSE:4062）</td>
<td>¥13855.00</td>
<td>¥27366.14</td>
<td>49.4%</td>
</tr>
<tr>
<td>国泉食品（上海）（SEHK:2517）</td>
<td>HK$4.00</td>
<td>HK$7.97</td>
<td>49.8%</td>
</tr>
<tr>
<td>重庆白鸭卫生用品（SZSE:003006）</td>
<td>CN¥22.33</td>
<td>CN¥44.01</td>
<td>49.3%</td>
</tr>
<tr>
<td>阿里巴巴健康信息技术（SEHK:241）</td>
<td>HK$5.73</td>
<td>HK$11.23</td>
<td>49%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们基于现金流的 279 只被低估亚洲股票的完整列表。</p>
<p>我们将查看我们筛选工具中的一些最佳选择。</p>
<h2>巨子生物（SEHK:2367）</h2>
<p><strong>概述：</strong> 巨子生物控股有限公司是一家投资控股公司，设计、开发、制造和销售以重组胶原蛋白为特色的皮肤治疗产品，市场覆盖中华人民共和国，市值为 408.7 亿港元。</p>
<p><strong>运营：</strong> 公司的收入主要来自个人产品部门，产生了 61.1 亿人民币的收入。</p>
<p><strong>公允价值折扣估计：</strong> 41.8%</p>
<p>巨子生物的交易价格低于其估计公允价值的 41.8%，当前价格为 38.16 港元，估计公允价值为 65.51 港元。最近的收益增长为 27.9%，预计年利润增长为 17.1%，超过香港市场平均水平，尽管收入增长预测为 18.2%，但现金流潜力依然强劲。分析师一致认为，预计价格将上涨 83.4%，进一步增强了其相对于同行和行业标准的相对价值。</p>
<ul>
<li>我们的综合增长报告表明，巨子生物有望实现显著的财务增长。</li>
<li>解锁我们对巨子生物股票分析的全面见解，查看这份财务健康报告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6553fa54-fe12-48d3-ad44-4efb3ec7ce4a/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6553fa54-fe12-48d3-ad44-4efb3ec7ce4a/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SEHK:2367 截至 2025 年 11 月的折现现金流</p>
<h2>西安诺瓦星云科技（SZSE:301589）</h2>
<p><strong>概述：</strong> 西安诺瓦星云科技有限公司设计和开发 LED 显示控制解决方案，市场覆盖中国及国际，市值为 156.7 亿人民币。</p>
<p><strong>运营：</strong> 公司的收入主要来自视频图像显示控制行业，总计 33.2 亿人民币。</p>
<p><strong>公允价值折扣估计：</strong> 43.1%</p>
<p>西安诺瓦星云科技的交易价格低于其估计公允价值的 43.1%，当前价格为 173 元，估计公允价值为 304.2 元，显示出其基于现金流的低估。尽管最近净收入有所下降，但预计年收益将显著增长 29.3%，超过中国市场的平均水平，表明未来现金流潜力强劲。然而，预计三年后的股本回报率相对较低，为 18%。</p>
<ul>
<li>我们编制的增长报告表明，西安诺瓦星云科技的未来前景可能向好。</li>
<li>点击这里访问我们的完整资产负债表健康报告，以了解西安诺瓦星云科技的动态。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ef33fac9-2042-487f-849d-74481c44134a/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ef33fac9-2042-487f-849d-74481c44134a/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SZSE:301589 截至 2025 年 11 月的折现现金流</p>
<h2>WT 微电子（TWSE:3036）</h2>
<p><strong>概述：</strong> WT 微电子有限公司在美国、台湾、中国及其他国际市场开发和销售电子及通信组件，市值为 1727.3 亿新台币。</p>
<p><strong>运营：</strong> 公司的收入部门包括在美国、台湾、中国及其他国际市场的电子和通信组件销售。</p>
<p><strong>公允价值折扣估计：</strong> 43.8%</p>
<p>WT 微电子的交易价格为 154 新台币，显著低于其估计公允价值 274.12 新台币，显示出其基于现金流的低估。最近的收益报告显示，2025 年第三季度的净收入为 38.2 亿新台币，较去年增长了 28.1%。预计年收益将显著增长 26.9%，超过台湾市场的平均增长率，尽管高债务水平和温和的股本回报率预测为 16.7%。</p>
<ul>
<li>我们最近的增长报告提供了 WT 微电子业务前景的良好预测。</li>
<li>深入了解 WT 微电子的具体情况，请查看我们的详细财务健康报告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3d299a68-3ac1-4aa0-9689-35787acddbd6/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3d299a68-3ac1-4aa0-9689-35787acddbd6/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>TWSE:3036 截至 2025 年 11 月的折现现金流</p>
<h2>关键要点</h2>
<ul>
<li>解锁更多宝藏！我们的基于现金流的被低估亚洲股票筛选工具为您挖掘了 276 家公司供您探索。点击这里揭示我们精心策划的 279 只基于现金流的被低估亚洲股票列表。</li>
<li>对这些企业有投资吗？将您的持股整合到 Simply Wall St 的投资组合中，以获取通知和详细的股票报告。</li>
<li>通过 Simply Wall St 提升您的投资组合，这是寻求全球市场覆盖的投资者的终极应用。</li>
</ul>
<h2>对其他可能性感兴趣吗？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过稳健的分红支付者来多样化您的投资组合，以提供可靠的收入来源，以应对潜在的市场波动。</li>
<li>充实您的投资组合，选择那些显示出强劲增长潜力的公司，这些公司得到了分析师和管理层的乐观展望支持。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章并不构成财务建议。它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。</strong> 我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

巨子生物

诺瓦星云

<p>随着亚洲市场表现不一，投资者正在寻找被低估的股票以实现潜在的资本增值。关键推荐包括巨子生物、陕西诺瓦星云科技和 WT 微电子，这些公司的交易价格均显著低于其估计的公允价值。这些公司展现出强劲的基本面和预期的盈利增长，表明其现金流潜力强大。文章强调了深入分析的重要性，并列出了 279 只在亚洲被低估的股票，鼓励投资者在不断变化的市场环境中探索机会</p>

<p>As the Asian markets navigate a landscape marked by mixed performances and economic shifts, investors are closely watching for opportunities amid easing U.S.-China trade tensions and Japan's record stock market highs. In this context, identifying undervalued stocks with strong fundamentals can offer potential for capital appreciation, especially as regional economies adapt to evolving global conditions.</p>
<div class="lb-trans"><p>随着亚洲市场在表现不一和经济变动的背景下进行调整，投资者密切关注在美中贸易紧张局势缓解和日本股市创纪录高点的情况下寻找机会。在这种情况下，识别具有强大基本面的被低估股票可以提供资本增值的潜力，尤其是在区域经济适应不断变化的全球条件时。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3>
<div class="lb-trans"><h3>基于现金流的亚洲十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Xi'an International Medical Investment (SZSE:000516)</td>
<td>CN¥4.76</td>
<td>CN¥9.38</td>
<td>49.3%</td>
</tr>
<tr>
<td>Visional (TSE:4194)</td>
<td>¥9984.00</td>
<td>¥19579.10</td>
<td>49%</td>
</tr>
<tr>
<td>New Zealand King Salmon Investments (NZSE:NZK)</td>
<td>NZ$0.195</td>
<td>NZ$0.39</td>
<td>49.5%</td>
</tr>
<tr>
<td>Meitu (SEHK:1357)</td>
<td>HK$8.80</td>
<td>HK$17.19</td>
<td>48.8%</td>
</tr>
<tr>
<td>LianChuang Electronic TechnologyLtd (SZSE:002036)</td>
<td>CN¥10.08</td>
<td>CN¥19.99</td>
<td>49.6%</td>
</tr>
<tr>
<td>Insource (TSE:6200)</td>
<td>¥845.00</td>
<td>¥1665.99</td>
<td>49.3%</td>
</tr>
<tr>
<td>IbidenLtd (TSE:4062)</td>
<td>¥13855.00</td>
<td>¥27366.14</td>
<td>49.4%</td>
</tr>
<tr>
<td>Guoquan Food (Shanghai) (SEHK:2517)</td>
<td>HK$4.00</td>
<td>HK$7.97</td>
<td>49.8%</td>
</tr>
<tr>
<td>Chongqing Baiya Sanitary Products (SZSE:003006)</td>
<td>CN¥22.33</td>
<td>CN¥44.01</td>
<td>49.3%</td>
</tr>
<tr>
<td>Alibaba Health Information Technology (SEHK:241)</td>
<td>HK$5.73</td>
<td>HK$11.23</td>
<td>49%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估计）</strong></td>
<td><strong>折扣（估计）</strong></td>
</tr>
<tr>
<td>西安国际医疗投资（SZSE:000516）</td>
<td>CN¥4.76</td>
<td>CN¥9.38</td>
<td>49.3%</td>
</tr>
<tr>
<td>Visional（TSE:4194）</td>
<td>¥9984.00</td>
<td>¥19579.10</td>
<td>49%</td>
</tr>
<tr>
<td>新西兰国王三文鱼投资（NZSE:NZK）</td>
<td>NZ$0.195</td>
<td>NZ$0.39</td>
<td>49.5%</td>
</tr>
<tr>
<td>美图（SEHK:1357）</td>
<td>HK$8.80</td>
<td>HK$17.19</td>
<td>48.8%</td>
</tr>
<tr>
<td>联创电子科技有限公司（SZSE:002036）</td>
<td>CN¥10.08</td>
<td>CN¥19.99</td>
<td>49.6%</td>
</tr>
<tr>
<td>Insource（TSE:6200）</td>
<td>¥845.00</td>
<td>¥1665.99</td>
<td>49.3%</td>
</tr>
<tr>
<td>Ibiden 有限公司（TSE:4062）</td>
<td>¥13855.00</td>
<td>¥27366.14</td>
<td>49.4%</td>
</tr>
<tr>
<td>国泉食品（上海）（SEHK:2517）</td>
<td>HK$4.00</td>
<td>HK$7.97</td>
<td>49.8%</td>
</tr>
<tr>
<td>重庆白鸭卫生用品（SZSE:003006）</td>
<td>CN¥22.33</td>
<td>CN¥44.01</td>
<td>49.3%</td>
</tr>
<tr>
<td>阿里巴巴健康信息技术（SEHK:241）</td>
<td>HK$5.73</td>
<td>HK$11.23</td>
<td>49%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 279 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>点击这里查看我们基于现金流的 279 只被低估亚洲股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我们将查看我们筛选工具中的一些最佳选择。</p>
</div><h2>Giant Biogene Holding (SEHK:2367)</h2>
<div class="lb-trans"><h2>巨子生物（SEHK:2367）</h2>
</div><p><strong>Overview:</strong> Giant Biogene Holding Co., Ltd. is an investment holding company that designs, develops, manufactures, and sells skin treatment products featuring recombinant collagen in the People's Republic of China, with a market cap of HK$40.87 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 巨子生物控股有限公司是一家投资控股公司，设计、开发、制造和销售以重组胶原蛋白为特色的皮肤治疗产品，市场覆盖中华人民共和国，市值为 408.7 亿港元。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its Personal Products segment, which generated CN¥6.11 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自个人产品部门，产生了 61.1 亿人民币的收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 41.8%</p>
<div class="lb-trans"><p><strong>公允价值折扣估计：</strong> 41.8%</p>
</div><p>Giant Biogene Holding appears undervalued, trading at 41.8% below its estimated fair value of HK$65.51, with a current price of HK$38.16. Recent earnings growth of 27.9% and projected annual profit growth of 17.1% outpace the Hong Kong market average, highlighting strong cash flow potential despite slower revenue growth forecasts at 18.2%. Analysts agree on an expected price rise by 83.4%, reinforcing its relative value compared to peers and industry standards.</p>
<div class="lb-trans"><p>巨子生物的交易价格低于其估计公允价值的 41.8%，当前价格为 38.16 港元，估计公允价值为 65.51 港元。最近的收益增长为 27.9%，预计年利润增长为 17.1%，超过香港市场平均水平，尽管收入增长预测为 18.2%，但现金流潜力依然强劲。分析师一致认为，预计价格将上涨 83.4%，进一步增强了其相对于同行和行业标准的相对价值。</p>
</div><ul>
<li>Our comprehensive growth report raises the possibility that Giant Biogene Holding is poised for substantial financial growth.</li>
<li>Unlock comprehensive insights into our analysis of Giant Biogene Holding stock in this financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们的综合增长报告表明，巨子生物有望实现显著的财务增长。</li>
<li>解锁我们对巨子生物股票分析的全面见解，查看这份财务健康报告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6553fa54-fe12-48d3-ad44-4efb3ec7ce4a/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/6553fa54-fe12-48d3-ad44-4efb3ec7ce4a/chart/dcf?theme=light"/></p>
<p>SEHK:2367 Discounted Cash Flow as at Nov 2025</p>
<div class="lb-trans"><p>SEHK:2367 截至 2025 年 11 月的折现现金流</p>
</div><h2>Xi'an NovaStar Tech (SZSE:301589)</h2>
<div class="lb-trans"><h2>西安诺瓦星云科技（SZSE:301589）</h2>
</div><p><strong>Overview:</strong> Xi'an NovaStar Tech Co., Ltd. designs and develops LED display control solutions both in China and internationally, with a market cap of CN¥15.67 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 西安诺瓦星云科技有限公司设计和开发 LED 显示控制解决方案，市场覆盖中国及国际，市值为 156.7 亿人民币。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from the Video Image Display Control Industry, totaling CN¥3.32 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自视频图像显示控制行业，总计 33.2 亿人民币。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 43.1%</p>
<div class="lb-trans"><p><strong>公允价值折扣估计：</strong> 43.1%</p>
</div><p>Xi'an NovaStar Tech is trading at 43.1% below its estimated fair value of CNY 304.2, with a current price of CNY 173, highlighting its undervaluation based on cash flows. Despite recent net income declines, earnings are forecast to grow significantly at 29.3% annually, outpacing the Chinese market average and indicating strong future cash flow potential. However, return on equity is expected to be relatively low at 18% in three years.</p>
<div class="lb-trans"><p>西安诺瓦星云科技的交易价格低于其估计公允价值的 43.1%，当前价格为 173 元，估计公允价值为 304.2 元，显示出其基于现金流的低估。尽管最近净收入有所下降，但预计年收益将显著增长 29.3%，超过中国市场的平均水平，表明未来现金流潜力强劲。然而，预计三年后的股本回报率相对较低，为 18%。</p>
</div><ul>
<li>The growth report we've compiled suggests that Xi'an NovaStar Tech's future prospects could be on the up.</li>
<li>Click here and access our complete balance sheet health report to understand the dynamics of Xi'an NovaStar Tech.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们编制的增长报告表明，西安诺瓦星云科技的未来前景可能向好。</li>
<li>点击这里访问我们的完整资产负债表健康报告，以了解西安诺瓦星云科技的动态。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ef33fac9-2042-487f-849d-74481c44134a/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/ef33fac9-2042-487f-849d-74481c44134a/chart/dcf?theme=light"/></p>
<p>SZSE:301589 Discounted Cash Flow as at Nov 2025</p>
<div class="lb-trans"><p>SZSE:301589 截至 2025 年 11 月的折现现金流</p>
</div><h2>WT Microelectronics (TWSE:3036)</h2>
<div class="lb-trans"><h2>WT 微电子（TWSE:3036）</h2>
</div><p><strong>Overview:</strong> WT Microelectronics Co., Ltd. develops and sells electronic and communication components across the United States, Taiwan, China, and other international markets with a market cap of NT$172.73 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> WT 微电子有限公司在美国、台湾、中国及其他国际市场开发和销售电子及通信组件，市值为 1727.3 亿新台币。</p>
</div><p><strong>Operations:</strong> The company's revenue segments include electronic and communication components sales in the United States, Taiwan, China, and other international markets.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入部门包括在美国、台湾、中国及其他国际市场的电子和通信组件销售。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 43.8%</p>
<div class="lb-trans"><p><strong>公允价值折扣估计：</strong> 43.8%</p>
</div><p>WT Microelectronics is trading at NT$154, significantly below its estimated fair value of NT$274.12, highlighting its undervaluation based on cash flows. Recent earnings reports show strong performance with net income for Q3 2025 at NT$3.82 billion, up from NT$2.84 billion the previous year. Earnings are projected to grow significantly by 26.9% annually, surpassing Taiwan's market average growth rate and indicating robust future cash flow potential despite high debt levels and modest return on equity forecasts of 16.7%.</p>
<div class="lb-trans"><p>WT 微电子的交易价格为 154 新台币，显著低于其估计公允价值 274.12 新台币，显示出其基于现金流的低估。最近的收益报告显示，2025 年第三季度的净收入为 38.2 亿新台币，较去年增长了 28.1%。预计年收益将显著增长 26.9%，超过台湾市场的平均增长率，尽管高债务水平和温和的股本回报率预测为 16.7%。</p>
</div><ul>
<li>Insights from our recent growth report point to a promising forecast for WT Microelectronics' business outlook.</li>
<li>Dive into the specifics of WT Microelectronics here with our thorough financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们最近的增长报告提供了 WT 微电子业务前景的良好预测。</li>
<li>深入了解 WT 微电子的具体情况，请查看我们的详细财务健康报告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3d299a68-3ac1-4aa0-9689-35787acddbd6/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/3d299a68-3ac1-4aa0-9689-35787acddbd6/chart/dcf?theme=light"/></p>
<p>TWSE:3036 Discounted Cash Flow as at Nov 2025</p>
<div class="lb-trans"><p>TWSE:3036 截至 2025 年 11 月的折现现金流</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>关键要点</h2>
</div><ul>
<li>Unlock more gems! Our Undervalued Asian Stocks Based On Cash Flows screener has unearthed 276 more companies for you to explore.Click here to unveil our expertly curated list of 279 Undervalued Asian Stocks Based On Cash Flows.</li>
<li>Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.</li>
<li>Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁更多宝藏！我们的基于现金流的被低估亚洲股票筛选工具为您挖掘了 276 家公司供您探索。点击这里揭示我们精心策划的 279 只基于现金流的被低估亚洲股票列表。</li>
<li>对这些企业有投资吗？将您的持股整合到 Simply Wall St 的投资组合中，以获取通知和详细的股票报告。</li>
<li>通过 Simply Wall St 提升您的投资组合，这是寻求全球市场覆盖的投资者的终极应用。</li>
</ul>
</div><h2>Interested In Other Possibilities?</h2>
<div class="lb-trans"><h2>对其他可能性感兴趣吗？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过稳健的分红支付者来多样化您的投资组合，以提供可靠的收入来源，以应对潜在的市场波动。</li>
<li>充实您的投资组合，选择那些显示出强劲增长潜力的公司，这些公司得到了分析师和管理层的乐观展望支持。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章并不构成财务建议。它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。</strong> 我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

亚洲市场价值股的选择以实现潜在的资本增值